Imagine a world where life-changing medications are copied, sold at a fraction of the cost, and marketed as safe—but they're not. This is the alarming reality Novo Nordisk is fighting against as it sues Hims & Hers for allegedly peddling cheaper, unapproved versions of its blockbuster obesity drug, Wegovy. But here's where it gets controversial: Hims claims its products are legal because they're 'personalized,' while Novo Nordisk calls it a dangerous sham. Who's right? And what does this mean for patients?
On Monday, pharmaceutical giant Novo Nordisk announced it is taking legal action against online telehealth provider Hims & Hers for allegedly mass-marketing unauthorized copies of its Wegovy obesity pill and injections in the U.S. Novo Nordisk is seeking a permanent injunction to stop Hims from selling these compounded versions, which it claims infringe on its patents, and is also pursuing damages. This move intensifies an ongoing feud between the two companies, sparked by Hims' recent decision to halt its copycat obesity pill after facing scrutiny from federal regulators and legal threats from the Danish drugmaker.
The heart of the issue lies in the regulatory gray area surrounding compounded drugs. Compounding is typically allowed when a doctor determines it's medically necessary for a specific patient—like adjusting a dosage for someone who can't swallow pills. However, Novo Nordisk argues that Hims is exploiting this loophole to mass-produce and sell untested versions of Wegovy, putting patients at risk. John Kuckelman, Novo's group general counsel, bluntly stated, 'This is a complete sham, and it has been a sham since the shortage ended.' He emphasized that these compounded medicines lack the safety and efficacy verification required by U.S. regulators.
Hims had planned to offer its oral obesity drug for as little as $49 for the first month—significantly undercutting Novo's Wegovy pill, which costs roughly $150. This price difference highlights the financial incentives driving the controversy. Meanwhile, Novo Nordisk's shares surged by over 5% following the lawsuit, while Hims' stock plummeted 21% in premarket trading.
But this isn’t just about money—it’s about patient safety and market integrity. Novo Nordisk is battling to reclaim its market share in the booming obesity drug sector, where competitors like Eli Lilly and compounded alternatives are gaining ground. The lawsuit comes as Novo works to close a regulatory loophole that allows companies to sell compounded versions of patent-protected drugs during shortages. While the active ingredient in Wegovy, semaglutide, is no longer in short supply in the U.S., Novo estimates that 1.5 million Americans are still using compounded GLP-1 drugs, many of which contain semaglutide despite its patent protection until 2032.
Hims defends its actions by claiming its compounded products are legal because they are 'personalized' in dosage. However, Novo Nordisk counters that Hims is engaging in illegal mass compounding, not legitimate case-by-case production. Kuckelman clarified, 'We want an end to unlawful mass compounding, not all compounding practices.' He stressed that compounding must be based on legitimate medical need, not as a way to circumvent patents and flood the market with untested products.
The Food and Drug Administration (FDA) has also taken a stand, announcing plans to restrict access to GLP-1 ingredients used in non-approved compounded drugs and referring Hims to the Department of Justice for potential violations. Meanwhile, some telehealth platforms, like Ro, are transitioning to FDA-approved products, but others, like Hims, continue to resist. Kuckelman warned, 'The only way it appears we're going to get Hims and others to stop this is through government enforcement actions and lawsuits like the one we've filed today.'
This battle raises critical questions: Are compounded drugs a lifeline for patients in need, or a dangerous loophole for profit-driven companies? Novo Nordisk and Eli Lilly have filed over 130 lawsuits combined against compounding pharmacies in the past two years, accusing them of deceptive marketing and consumer fraud. As the obesity drug market continues to explode, the outcome of this legal battle could reshape how we balance innovation, accessibility, and safety in healthcare.
What do you think? Is Hims providing a necessary alternative, or crossing a dangerous line? Let us know in the comments—this debate is far from over.
